Market evolution: Medicaments in dosage (CN 3004) — 2015–2025

Introduction

This report analyses the trade evolution of medicaments in dosage (CN 3004) by the European Union with non-EU countries over the period 2015-2025. The data reveals a period of substantial growth for the EU's pharmaceutical trade, characterized by a dominant export position, rising unit values, and significant structural shifts in product composition and geographical partners. The EU has consolidated its role as a major global exporter of finished pharmaceutical products, achieving a more than doubling of its trade surplus.

Robust Export Expansion Outpaces Import Growth

The decade under review was marked by strong and sustained growth in EU exports of medicaments, significantly outpacing the growth in imports. This expansion was driven by both higher volumes and a marked increase in export prices, solidifying the EU's position as a net exporter.

Exports Show Strong Value Growth Rooted in Price Increases

EU exports of CN 3004 products surged from €96.8 billion in 2015 to €179.6 billion in 2025, representing an increase of 85.6%. A significant portion of this value growth was attributable to rising prices. The average export price per tonne increased from €105,738 in 2015 to €156,639 in 2025, a 48.1% rise. Export volumes also grew, by 25.3% from 915,089 tonnes to 1,146,713 tonnes, indicating a shift towards higher-value products.

Import Values Rise Despite Stagnant Volumes

In contrast, EU imports grew more moderately, increasing from €37.4 billion to €53.3 billion (+42.7%). This growth was almost entirely driven by price inflation, as import volumes actually contracted by 8.5% from 277,895 to 254,325 tonnes. The average import price per tonne soared by 55.9%, from €134,548 to €209,762.

The EU Trade Surplus More Than Doubles

The differential growth patterns between exports and imports led to a dramatic expansion of the EU's trade surplus. The surplus grew from €59.4 billion in 2015 to €126.3 billion in 2025, an increase of 112.7%. This underscores the EU's strengthening role as a key global supplier of high-value pharmaceuticals.

Shifting Geographical Partnerships and Internal EU Dynamics

The growth in trade was accompanied by notable shifts in the EU's main trading partners. While traditional partners like the United States and the United Kingdom remained crucial, significant growth occurred with other economies, altering the landscape of EU pharmaceutical trade.

Export Destinations: Switzerland Becomes the Dominant Partner

The most striking geographical shift was in exports to Switzerland, which grew by an extraordinary 409.9%, rising from €9.2 billion to €46.7 billion. This made Switzerland the EU's single largest export market by 2025, surpassing the United States, which still saw strong growth of 75.0%. Other key growth markets included China (+86.2%) and Korea (+87.1%).

Import Sources: Diversification and Rising Role of India and Serbia

On the import side, Switzerland also saw a major increase in its share, with imports growing by 124.4%. However, the most dynamic growth came from India (+197.3%) and Serbia (+258.9%). The United States remained the largest import source by value in 2025, though its growth was more modest at 17.3%.

Internal EU Specialisation: Germany Leads, but Italy and Others Show Remarkable Growth

Within the EU, Germany remained the leading exporter, with its exports growing to €34.0 billion (+20.3%). However, the most dramatic growth was seen in Italy, whose exports surged by 345.1% to €24.8 billion, and the Netherlands (+105.0%). In imports, Slovenia saw an astronomical increase of 2,605%, likely reflecting the role of specific trading or production hubs.

Significant Structural Shifts in Product Composition and Market Volatility

A deeper analysis of the product segments reveals a fundamental shift in the composition of traded medicaments, alongside periods of significant price volatility in specific bilateral relationships.

"Other Medicaments" Dominance and the Surge in Hormone Imports

The product segment CN 300490 ("other medicaments") consistently represented the vast majority of both EU imports and exports by value. Within imports, the segment for hormones (CN 300439) experienced a dramatic value increase from €1.9 billion in 2015 to €6.0 billion in 2025, largely driven by a 130% rise in unit price. This indicates a growing reliance on high-value, specialized hormone-based treatments.

Export Product Mix: Alkaloids and Vitamins Show Distinct Trajectories

For exports, the alkaloids segment (CN 300449) showed relatively stable volumes and prices. In contrast, vitamin medicaments (CN 300450) saw a decline in export volumes but a recovery in prices towards the end of the period, suggesting a possible shift towards higher-value formulations.

Price Shocks and Volatility in Bilateral Trade

The volatility analysis identifies several partners with high coefficient of variation (CV) in trade values, indicating less stable relationships. Notably, EU exports to Serbia and Vietnam experienced extreme price shocks in 2018 and 2022 respectively, characterized by sudden and dramatic price spikes. These events, while small in overall trade share, highlight the potential for geopolitical or market-specific disruptions in niche segments.

Conclusion

Between 2015 and 2025, the EU's trade in medicaments (CN 3004) evolved into a more consolidated, high-value export powerhouse. The period was defined by robust export-led growth, a more than doubling of the trade surplus, and a significant increase in unit values across both exports and imports. Geographically, trade intensified dramatically with Switzerland and showed strong growth with emerging partners like India and Serbia. Structurally, the EU became a much larger importer of high-value hormone medicaments while its export base remained concentrated in the broad "other medicaments" category. The data points to an EU pharmaceutical sector that successfully navigated the decade by leveraging its competitive advantage in high-value finished dose pharmaceuticals, even as it faced new price dynamics and occasional volatility in specific trade flows.